INS and type 2 diabetes mellitus: For instance, acipimox treatment in obese nondiabetic persons alleviated free fatty acids and fasting glucose with a trend toward reduced fasting insulin and homeostatic model assessment of insulin resistance [77], whereas van de Weijer et al. [78] did not report similar benefits in individuals with T2DM by using euglycemic hyperinsulinemic clamp studies.